A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis (NCT03772587), a randomized phase 2 study. The primary outcome is Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability.

2. Clinical Question

The registry record describes a study of adults with generalized myasthenia gravis (gMG) whose response to ongoing standard-of-care therapy was insufficient. The primary question concerned safety and tolerability: how many participants experienced a treatment-emergent adverse event after starting study treatment? The posted primary results compare placebo with four nipocalimab-labelled groups. The secondary measures include changes in disease-related scores and serum immunoglobulin G (IgG).

The clinical question is not limited to whether adverse events occurred. The secondary outcomes include measures of myasthenia gravis symptoms and quality of life at Day 57, as well as serum IgG. These outcomes describe different aspects of the study and should not be treated as interchangeable measures. The primary endpoint is a participant count, while the secondary measures include score changes and biomarker changes. The posted record does not report the study's own prespecified efficacy analysis results for these comparisons.

3. Trial Design

This was a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The registry lists quadruple masking. The study is marked completed, with a recorded enrollment of 68. Its start date is 2019-04-10 and its primary completion date is 2020-06-25. The record does not report the allocation ratio or explain how the listed masking roles were defined.

The posted results contain five groups: placebo; nipocalimab 5 mg/kg; nipocalimab 30 mg/kg; nipocalimab 60 mg/kg; and nipocalimab 60 mg/kg (Q2W). For the primary safety endpoint, the denominators are 14, 14, 13, 13, and 14, respectively. The registry's general enrollment figure and the endpoint-specific denominators describe different aspects of the record; endpoint counts should be read with their stated group denominators. Descriptions for the registry's listed groups are blank, so further details about treatment schedules or group procedures are not reported in the registry record.

The title and official title identify the study intervention as M281, whereas the result groups use the name nipocalimab. The record does not explain the naming relationship, so the labels are best kept as they appear in their respective parts of the registry. The brief summary says participants had an insufficient clinical response to ongoing standard-of-care therapy; further eligibility criteria and the details of that background therapy are not reported in the registry record.

Randomization and masking are design features intended to reduce systematic differences between groups and bias in outcome assessment. General explanation: randomization can balance measured and unmeasured participant characteristics on average, but it does not guarantee balance in a small study. The group sizes in these results are modest, so estimates may be sensitive to the outcomes of a small number of participants. The record does not report the original statistical design assumptions or how the study handled interim analyses.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: The safety population included all participants who received any amount of nipocalimab or placebo.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Intent-to-treat (ITT) population included all randomized participants.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants With Treatment-emergent Adverse Events (TEAEs) as a Measure of Safety and Tolerability, measured over Up to Day 113.

The primary endpoint is the number of participants with treatment-emergent adverse events (TEAEs), assessed up to Day 113. The registry defines an adverse event as an untoward medical event occurring in a participant who received an investigational product; an event does not necessarily have a clear causal relationship to that product. A TEAE is an adverse event occurring during or after initiation of the first study-drug infusion. The safety population includes participants who received any amount of nipocalimab or placebo.

This endpoint is used to describe safety and tolerability during the recorded observation period. Counting participants with at least one event gives a simple group-level summary, but it does not describe the total number of events, their duration, severity, or whether they were judged related to treatment. Those details are not part of the primary endpoint definition presented in the record. Serious adverse events are reported separately in the registry's safety information and should not be substituted for the broader TEAE count.

The posted primary results record 11 participants with TEAEs in the placebo group, 12 in the 5 mg/kg group, 9 in the 30 mg/kg group, 12 in the 60 mg/kg group, and 12 in the 60 mg/kg (Q2W) group. The respective group denominators are 14, 14, 13, 13, and 14. These counts describe observed participants in the safety population; they do not alone establish whether an event was caused by treatment or whether groups differ reliably.

7. Results Posted in the Registry

• Nipocalimab 5 Milligrams/Kilogram (mg/kg): 85.7% (12/14) versus 78.6% (11/14) on control; risk difference 7.1 percentage points (95% CI -21.1 to 35.4), risk ratio 1.09 (0.77–1.54); unadjusted two-proportion z-test p = 0.622.
• Nipocalimab 30 mg/kg: 69.2% (9/13) versus 78.6% (11/14) on control; risk difference -9.3 percentage points (95% CI -42.4 to 23.7), risk ratio 0.88 (0.56–1.39); unadjusted two-proportion z-test p = 0.580.
• Nipocalimab 60 mg/kg: 92.3% (12/13) versus 78.6% (11/14) on control; risk difference 13.7 percentage points (95% CI -12.2 to 39.7), risk ratio 1.17 (0.86–1.61); unadjusted two-proportion z-test p = 0.315.
• Nipocalimab 60 mg/kg (Q2W): 85.7% (12/14) versus 78.6% (11/14) on control; risk difference 7.1 percentage points (95% CI -21.1 to 35.4), risk ratio 1.09 (0.77–1.54); unadjusted two-proportion z-test p = 0.622.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Change From Baseline in Total QMG Score at Day 57

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Nipocalimab 5 mg/kg: mean -3.50 versus -3.70 on control; difference 0.20 (95% CI -2.63 to 3.03), standardized effect d = 0.06; z-test p = 0.890.
  • Nipocalimab 30 mg/kg: mean -4.10 versus -3.70 on control; difference -0.40 (95% CI -3.16 to 2.36), standardized effect d = -0.13; z-test p = 0.776.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Nipocalimab 5 mg/kg and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Nipocalimab 30 mg/kg and the control. The interval gives the range of effects that remain compatible with the data.

Change From Baseline in Total Revised Myasthenia Gravis Quality of Life - 15 (MG-QoL-15r) Scale Score at Day 57

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Nipocalimab 5 mg/kg: mean -1.70 versus -2.00 on control; difference 0.30 (95% CI -3.17 to 3.77), standardized effect d = 0.07; z-test p = 0.866.
  • Nipocalimab 30 mg/kg: mean -6.80 versus -2.00 on control; difference -4.80 (95% CI -9.02 to -0.58), standardized effect d = -0.92; z-test p = 0.026.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Nipocalimab 5 mg/kg and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for Nipocalimab 30 mg/kg than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Change From Baseline in Total Serum IgG at Day 57

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Nipocalimab 5 mg/kg: mean -1.50 versus -0.30 on control; difference -1.20 (95% CI -2.37 to -0.03), standardized effect d = -0.82; z-test p = 0.044.
  • Nipocalimab 30 mg/kg: mean -3.40 versus -0.30 on control; difference -3.10 (95% CI -4.31 to -1.89), standardized effect d = -2.05; z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for Nipocalimab 5 mg/kg than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for Nipocalimab 30 mg/kg than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

The secondary outcomes span clinical scores and a laboratory measure. QMG and MG-ADL assess myasthenia gravis-related status, MG-QoL-15r addresses quality of life, and serum IgG provides a biological measure. The registry also lists response thresholds for score improvements and analyses relating score changes to serum IgG. These outcomes offer complementary perspectives, but they do not measure the same construct as the primary safety endpoint.

Across the posted continuous outcomes, the direction and size of group differences are not uniform. The available summaries and recalculated contrasts therefore do not form one consistent, confirmatory pattern across all measures. In particular, the registry includes secondary comparisons with unadjusted intervals and p-values, but no reported analyses. This limits how much weight can be placed on any isolated result, especially when many outcomes and treatment groups are considered.

The secondary findings do not replace or directly explain the primary safety result. The primary endpoint counts participants with TEAEs through up to Day 113, whereas several secondary measures describe change at Day 57. Safety and symptom or biomarker measures answer different questions and use different timeframes and endpoint scales. A difference on one secondary measure does not establish a corresponding difference in overall clinical status or in adverse-event risk.

Unadjusted secondary results carry less weight because the registry does not report how multiple testing was handled. General explanation: with many comparisons, some results can appear notable by chance even if there is no underlying difference. The posted record also does not report the trial's prespecified hierarchy of outcomes or a confirmatory statistical plan. These limitations make the secondary results most useful as descriptive or hypothesis-generating information, rather than as stand-alone evidence for a definitive conclusion.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Change From Baseline in Total MG-ADL Score as a Function of Total Serum Immunoglobulin G (IgG) at Day 57
• Change From Baseline in Total MG-ADL Score as a Response to Percent Change in Total Serum IgG, for Participants Positive for Anti-acetylcholine Receptor (Anti-AChR) Antibodies, at Day 57
• Change From Baseline in Total Quantitative Myasthenia Gravis (QMG) Score as a Function of Total Serum IgG at Day 57
• Change From Baseline in Total QMG Score as a Response to Percent Change in Total Serum IgG, for Participants Positive for Anti-acetylcholine Receptor (Anti-AChR) Antibodies, at Day 57
• Number of Participants With a 2-, 3-, 4-, 5-, 6-, 7-, or Greater Than or Equal to (>=) 8-point Improvement in Total MG-ADL Score at Day 57
• Change From Baseline in Total QMG Score at Day 57
• Number of Participants With a 3-, 4-, 5-, 6-, 7-, or >= 8-point Improvement in Total QMG Score at Day 57
• Change From Baseline in Total Revised Myasthenia Gravis Quality of Life - 15 (MG-QoL-15r) Scale Score at Day 57

9. Statistical Interpretation

10. Statistical Methods Explained

The primary outcome is binary at the participant level: each person either had at least one TEAE during the defined period or did not. The posted group counts and denominators give the observed event proportions. The pairwise summaries compare each active group with placebo using a risk difference. A risk difference expresses the difference between two event proportions on the probability scale; zero represents equal observed proportions. General explanation: this measure is directly interpretable as an absolute contrast, but in small samples its estimate can be imprecise.

The confidence intervals and unadjusted p-values accompanying the risk differences are recalculated from posted summary statistics. The record does not provide a reported analysis method for these contrasts. It also does not report covariate adjustment, stratification factors, a prespecified statistical model, or the handling of missing primary-outcome data. The recalculated comparisons should therefore not be mistaken for an analysis specified or endorsed in the registry record. The discrepancy indicator is false, so no conflict between the posted summaries and these recalculations is flagged; nevertheless, the registry's sponsor-reported analysis would take precedence if one were available.

A confidence interval describes a range of estimates compatible with the observed data under the calculation's assumptions. General explanation: a wide interval indicates that the data do not pin down the contrast precisely. When an interval includes zero, it includes no difference as one plausible value, but that does not demonstrate equality. Conversely, an interval excluding zero does not by itself establish clinical importance, especially when many outcomes and comparisons are examined.

The secondary continuous outcomes are reported as mean changes from baseline with standard deviations. These include QMG score, MG-QoL-15r score, and serum IgG at Day 57. The recalculated comparisons use mean differences between an active-treatment group and placebo, with unadjusted confidence intervals and p-values. A mean difference is the difference between group averages; the standard deviation describes variability among observations within a group, not uncertainty in the mean itself. General explanation: the standard error of a mean depends on both the variability of observations and the number of observations, so smaller groups generally yield less precise estimates.

The registry's posted secondary summaries do not include reported analyses. The values described as recalculated are simple, unadjusted re-calculations based on the posted summary statistics. They do not represent adjusted treatment-effect estimates from a stated trial model. In particular, a comparison of group averages does not adjust for baseline characteristics or repeated measurements unless an analysis method explicitly says so; such a method is not reported in the registry record. The data do not state whether changes were analyzed using a model that accounted for baseline scores, site, or other variables.

General explanation: over-dispersion matters when outcome variation is greater than a model's assumptions allow. In count outcomes, extra variation can make standard errors too small if a simple model is used. The primary endpoint is reported as the number of participants with an event, not as an event-count rate, so the registry's posted primary summary is not an event-rate model. No over-dispersion assessment or model is reported.

Multiplicity is the challenge created when many outcomes, groups, or timepoints are tested. If each comparison is considered independently without adjustment, the chance of at least one apparently unusual result across a set of tests can increase. General explanation: a multiplicity plan may define a primary comparison, a hierarchy, or an adjustment method before examining results. The registry record does not report such a plan. Consequently, the unadjusted secondary p-values should be treated cautiously and cannot by themselves support confirmatory claims.

Missing-data handling is also not described in the posted record. The reported denominators differ among outcome summaries, and the record does not explain whether these differences arise from missing measurements, eligibility for a particular measure, or another reason. No imputation procedure, sensitivity analysis, or analysis-population rule for the secondary outcomes is reported. The primary safety population is defined, but information about exclusions or participant flow is not reported in the registry record.

Finally, the original sample-size justification and trial-specific assumptions are not reported in the registry record. The planning illustrations associated with the recalculated effects use stated assumptions, but they are not evidence about the study's original design. General explanation: an observed effect from a small study can be unstable, so planning directly from it may produce sample-size illustrations that are overly optimistic or otherwise unrepresentative. Such illustrations are useful for understanding the relationship between assumed effects and required sample size, not for retroactively judging the trial's success.

11. Confidence Intervals and Precision

The primary risk-difference intervals are broad in relation to their point estimates. For the 5 mg/kg group, the estimate is 0.071 with a 95% confidence interval from -0.211 to 0.354. For 30 mg/kg, it is -0.093, with an interval from -0.424 to 0.237. For 60 mg/kg, it is 0.137, with an interval from -0.122 to 0.397. For 60 mg/kg (Q2W), it is 0.071, with an interval from -0.211 to 0.354. All include zero and allow both negative and positive differences.

General explanation: a confidence interval reflects sampling uncertainty under the assumptions of the calculation. It is not a range that guarantees where the true value lies, nor does an interval containing zero show that the groups are equivalent. Here, the limited group sizes mean the observed event counts cannot tightly distinguish among a range of possible group differences. A point estimate alone can make the result look more settled than the interval warrants.

The same caution applies to continuous secondary comparisons. The reported confidence intervals for some mean differences span zero, while others do not; the widths vary across outcomes and group comparisons. The registry does not report adjusted analyses, and these recalculated intervals are unadjusted. They therefore address uncertainty in each individual contrast, not the additional uncertainty introduced by examining multiple outcomes and groups.

Precision is distinct from clinical importance. An interval can be narrow around a small difference or broad enough to include materially different possibilities; interpretation requires both the scale and the endpoint definition. The registry does not state a threshold for a clinically meaningful difference on the secondary scales, so the posted estimates alone cannot establish whether a score change is meaningful to participants.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The sample-size planning figures are participants per arm for the binary and continuous comparisons in this study; they are not total event counts. The stated planning assumptions are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. The assumed effect is the stated fraction of the observed effect. The trial's own original design assumptions and sample-size justification are not reported in the registry record.

The 80% power column gives an illustrative number of participants per arm for a design intended to have an 80% chance of detecting the assumed effect at the stated significance level, if the planning assumptions hold. The 90% power column gives the corresponding illustration for a 90% chance. General explanation: power is a design property calculated under assumed conditions; it is not the probability that a particular result is true or that a finding is real.

Rows for planning at 100%, 75%, and 50% of the observed effect illustrate how the assumed effect size changes the planning requirement. A smaller assumed effect requires more participants to detect, other assumptions being held constant. For example, the binary comparison of 5 mg/kg with placebo lists 451 participants per arm for 80% power when planning for 100% of the observed effect, and 833 participants per arm when planning for 75% of that effect. These are illustrations derived from observed estimates, not the study's original enrollment target. This is not observed power.

Planning curves can be read in the same way: they show how a calculated sample-size requirement changes as the assumed effect changes under the selected assumptions. They do not forecast a future study's result, correct for multiplicity, or account for design details not included in the stated assumptions. Because the observed effects come from small groups, the planning estimates can be sensitive to uncertainty in those effects.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, p₀ and p₁ are the control and treatment proportions, and p̄ is their average.

Worked calculation for this trial

1. Control proportion p₀ = 0.786; treatment proportion p₁ = 0.857; average p̄ = 0.821.
2. First term: z_1−α/2 × √[2p̄(1−p̄)] = 1.96 × 0.5416 = 1.0616.
3. Second term: z_1−β × √[p₀(1−p₀) + p₁(1−p₁)] = 0.842 × 0.5393 = 0.4539.
4. n = (1.0616 + 0.4539)² / (0.0714)² = 450.1, rounded up to 451 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
p0 <- 0.785714285714286                          # control proportion
p1 <- 0.857142857142857                          # treatment proportion
n_per_arm <- function(power, frac = 1) {
  q1 <- p0 + (p1 - p0) * frac               # smaller effect = fraction of the observed difference
  pbar <- (p0 + q1) / 2
  z_b <- qnorm(power)
  ceiling(round((z_a * sqrt(2 * pbar * (1 - pbar)) + z_b * sqrt(p0 * (1 - p0) + q1 * (1 - q1)))^2 / (q1 - p0)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (unrounded n per arm)
cat("power.prop.test:", round(power.prop.test(p1 = p0, p2 = p1, power = 0.80)$n, 1), "\n")

# Simulation: how often does the z-test reject at the 80%-power sample size?
set.seed(3772587)
n    <- n_per_arm(0.80)
reps <- 20000
x0 <- rbinom(reps, n, p0); x1 <- rbinom(reps, n, p1)
ph <- (x0 + x1) / (2 * n)
z  <- ((x1 - x0) / n) / sqrt(ph * (1 - ph) * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(z) > z_a, na.rm = TRUE), reps))

Output from running the code

100% of observed effect: n per arm = 451 (80% power), 603 (90% power)
 75% of observed effect: n per arm = 833 (80% power), 1,114 (90% power)
 50% of observed effect: n per arm = 1,942 (80% power), 2,599 (90% power)
power.prop.test: 450.1 
Simulated power at n = 451 per arm: 0.802 (20000 replicates)

The simulation draws many pairs of event counts at the planned sample size and counts how often the two-proportion z-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Multiplicity, Missing Data and Analysis Populations

The registry record lists 20 outcome measures, while 16 secondary outcomes are posted. Multiple outcomes, treatment groups, and measurement times create a multiplicity concern: the more comparisons considered, the easier it can be to encounter an apparently unusual result by chance. No multiplicity adjustment, testing hierarchy, or family-wise error strategy is reported in the registry record. The available p-values are unadjusted recalculations, not evidence that the trial's own analysis controlled the overall error rate.

The posted results contain no reported analyses for the primary comparisons and none for the displayed secondary comparisons. The registry record does not report a statistical analysis plan, a prespecified model, or details of any interim analyses. It is therefore not possible to determine from the record whether the displayed summaries were the planned primary analyses or how the study intended to interpret multiple endpoints.

The primary safety population is defined as participants who received any amount of nipocalimab or placebo. For secondary outcomes, the denominators vary across measures and groups. The record does not explain the reasons for these differences, how missing values were handled, whether participants were excluded from particular analyses, or whether any imputation or sensitivity analyses were performed. Participant flow and reasons for missing measurements are not reported in the registry record.

These gaps matter because analysis choices can influence estimates and uncertainty. General explanation: complete-case summaries can represent a selected subset if data availability is related to participant characteristics or outcomes, while imputation methods rely on their own assumptions. Without the record's missing-data approach, the secondary summaries should be interpreted as results among the participants represented in each outcome denominator, not automatically as results for every randomized participant.

The registry also does not report the original sample-size justification or study-specific assumptions about expected effects, variability, or power. The planning illustrations use stated assumptions based on observed effects and should not be confused with the original design plan.

15. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 2% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: musculoskeletal pain (7.7%), ischaemic stroke (7.1%), myasthenia gravis (7.1%).

The serious adverse-event counts are 2 of 14 in the placebo group, 0 of 14 in the nipocalimab 5 mg/kg group, 1 of 13 in the 30 mg/kg group, 0 of 13 in the 60 mg/kg group, and 0 of 14 in the 60 mg/kg (Q2W) group. The reported number of deaths is 0 in each group. These figures describe participants with serious adverse events, which is a narrower category than the primary endpoint's TEAEs. The serious-event counts should not be added to the broader TEAE counts or treated as a separate estimate of all adverse events.

The registry lists Musculoskeletal Pain at 7.7%, Ischaemic Stroke at 7.1%, and Myasthenia Gravis at 7.1% among the top serious-event terms. The record does not specify which treatment groups those terms correspond to in the information available for these results, so they cannot be assigned to a particular group from these figures alone.

General explanation: rare or serious events are difficult to compare reliably when group sizes are small. Zero observed events in a group does not establish that the underlying risk is zero. These safety counts describe observed events in the registry record and do not, by themselves, determine causality.

16. What the Result Does, and Does Not, Mean

The posted primary endpoint results show that TEAEs were recorded among participants in every group. Counts ranged from 9 of 13 in the 30 mg/kg group to 12 of 13 in the 60 mg/kg group, with placebo and the other active groups also having recorded events. The unadjusted risk-difference intervals are wide and include zero for every active-treatment comparison with placebo. The data therefore do not precisely establish the direction or size of differences in TEAE occurrence.

These results do not show that treatment caused every event. The registry's definition explicitly includes events without a clear causal relationship to the investigational product. Nor do the participant counts describe the total number of events, their duration, or their severity. The separate serious adverse-event counts add context, but the small group sizes do not support strong conclusions about rare safety outcomes.

The secondary score and serum IgG summaries describe outcomes at Day 57 and show variation among the posted groups. They do not make the primary safety findings into efficacy results. The registry record does not provide reported analyses for these comparisons, a multiplicity adjustment, or a stated threshold for clinically meaningful score changes. Thus, the recalculated secondary contrasts are uncertain and should not be treated as definitive evidence of benefit or lack of benefit.

More broadly, the study record documents a completed randomized phase 2 trial with a placebo group and four nipocalimab-labelled groups. The results are informative as descriptions of outcomes in the groups represented, but their precision is limited by the small denominators. The title's use of M281 and the posted treatment labels' use of nipocalimab are not reconciled in the registry record. These findings should be interpreted within those reporting and design limits, rather than generalized beyond the recorded study population or observation periods.

17. Why This Trial Matters Statistically

This trial illustrates why clinical trial results need to be read alongside their uncertainty, endpoint definitions, and analysis context. A participant count can look straightforward, yet it does not reveal event severity, causality, or the total event burden. The registry makes the TEAE definition explicit, allowing readers to distinguish the primary safety measure from serious adverse events and other safety summaries.

The comparison also shows the limits of small-group estimates. A risk difference is easy to state, but broad confidence intervals indicate that a wide range of group differences remains compatible with the data. Reporting the estimate together with its interval is therefore more informative than relying only on the observed counts or an unadjusted p-value.

The record also makes visible a common interpretive challenge in phase 2 studies: multiple arms and numerous secondary outcomes can yield a varied pattern of estimates. Without a reported analysis plan or multiplicity approach, isolated unadjusted findings deserve restraint. Secondary outcomes can help characterize biological and clinical measures, but they do not independently settle a question when their uncertainty and testing context are unclear.

Finally, the planning illustrations show how sample-size requirements depend on the effect assumed for a future comparison. They are useful for understanding design sensitivity, but they are not the trial's original planning justification and are not observed power. This distinction matters when readers use small exploratory studies to think about the design of later research.

18. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for interpreting these results is the small size of the posted groups, reflected in the denominators of 13 or 14 for the primary endpoint and varying denominators for secondary outcomes. This limits precision and makes results potentially sensitive to a small number of participants. The broad primary confidence intervals show that important differences in either direction remain compatible with the data.

The registry record does not report the original sample-size justification, a statistical analysis plan, the primary efficacy analysis, or multiplicity handling. It also does not report how missing data were handled for secondary measures, why outcome-specific denominators vary, or whether sensitivity analyses were conducted. These absences make it difficult to assess the planned inferential framework and the robustness of the posted comparisons.

The active-treatment naming is not consistent across the study title and the posted result labels: the title uses M281, while the groups are named nipocalimab. The registry record does not explain that relationship. Arm descriptions are blank, and the allocation ratio and additional treatment-schedule details are not reported in the registry record.

The primary safety endpoint captures participants with at least one TEAE, not event frequency, duration, severity, or causal attribution. The separate serious-event term percentages are not linked to groups in the reported information. Secondary findings use different measures and timeframes, and the record does not report thresholds for clinically meaningful score changes. These limitations constrain both between-group interpretation and generalization beyond the study's recorded population and observation periods.

19. Related Tutorials

20. Related Statistical Calculators

21. Sources

• ClinicalTrials.gov: A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis — NCT03772587.
• Registry record last updated 2023-06-27; status last verified 2023-05.
• Results first posted 2021-10-27.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

22. Record Summary

The registry record describes a completed, randomized, double-blind, placebo-controlled, multicenter, parallel-group phase 2 study in adults with generalized myasthenia gravis and insufficient response to ongoing standard-of-care therapy. It lists quadruple masking and an enrollment of 68. The recorded study dates are 2019-04-10 to primary completion on 2020-06-25.

The primary endpoint was the number of participants with TEAEs up to Day 113. Posted group counts range from 9 to 12 participants, with denominators from 13 to 14. Recalculated unadjusted risk-difference confidence intervals include zero for all four comparisons with placebo and are broad. The secondary outcomes include clinical scores, quality of life, and serum IgG, but the registry record reports no analyses for the displayed comparisons and does not report multiplicity or missing-data methods.

The trial offers descriptive safety and secondary-outcome information, but limited group sizes and unreported analysis details constrain inferential conclusions. The study title names M281, while the posted active-treatment groups use nipocalimab labels; the registry record does not explain this difference.